Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter

Dofetilide may be advantageous in terminating atrial fibrillation/atrial flutter (AFl) when there are contraindications for class I drugs (left ventricular dysfunction and/or manifest myocardial ischemia) and beta blockers. In particular, its successful outcome in usually drug-resistant AFl is promising and underscores the importance of selective class III action for terminating AFl.